PHAXIAM Therapeutics 20F 2022 Annual report | PHXM Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absorption, Actym, Adenine, agonist, AMR, antimicrobial, appeal, ASR, attenuated, attrition, bacterial, bid, biopharma, Bioscience, Bioserra, Capricor, Carmine, carryforward, categorized, Charton, CJEU, closure, codevelopment, Codiak, Commissioner, confronted, contractor, covenant, Coya, CSE, CSR, cure, DDS, deep, delisting, deployment, depth, derecognition, derecognized, detour, Didier, disciplinary, dominated, Eudravigilance, EV, EVs, excise, Exopharm, Fayet, Functionaly, gave, GIMV, GlaxoSmithKline, grace, Helsinn, Hoch, hub, idled, IDTA, immature, ImmuneSensor, impede, impression, indefinitely, ineligible, infectiology, inflammatory, Informatique, Inline, Intelligence, invaded, iPSP, jointly, judgement, Karine, lag, licensee, Linkbase, Maat, MC, MDImune, Medidata, Mersana, Microphyt, morale, motivate, naked, Nanoparticle, neurologic, NH, Nissle, Omnispirant, opined, outpace, pathogenic, penalize, phage, PhagoDAIR, player, PSE, Quantum, rapporteur, readout, recalculating, recognised, reconcile, reconciled, redundancy, reestimated, regain, regained, REGENT, remote, reorganization, resistance, resistant, restart, runway, Sanquin, Schema, semester, senescence, sensitive, Shield, ShiftBio, shortly, spring, standalone, Steering, STINGa, successor, Synlogic, Takeda, Taxonomy, technique, Theraguix, Thibaut, Township, transformation, Troy, true, trybeca, Typhimurium, unbilled, unmodified, unplanned, valorization, vesiculation, West, Windsor, withstand, XBRL

Removed: AADA, abraxane, absolute, adenocarcinoma, ADI, administrated, advancement, ahead, Alexion, alternating, alternation, anaphylactic, anemia, anniversary, arginine, astrazeneca, BioLineRx, BRCA, broaden, built, BVF, capivasertib, centered, China, companion, comprise, conceptual, constructed, contaminated, Cornell, culture, defective, deiminase, demonstrably, designing, desire, developmental, devoting, discontinue, distancing, distinction, documented, donation, EGC, Eleison, experiencing, extinguish, FIFO, filer, fixture, Floor, fluorouracil, flurouracil, Francisco, furlough, gamma, geographic, germline, globally, glufosfamide, glutamyl, golden, hemorrhage, hiring, interrupted, intravenously, ipatasertib, irinotecan, Jazz, Jumpstart, Lampert, leucovorin, liposomal, LP, Lynparza, mark, meantime, methionine, MGL, mutant, myeloid, neutropenia, nonbinding, nonconvertible, obsolescence, Onivyde, operator, oppose, opted, optionally, outbreak, oxaliplatin, parachute, PARP, pecuniary, periodically, PLC, polymerase, predicted, premature, prematurely, publication, Radboud, realizable, reclassified, regulator, repeat, restructured, ribose, robust, San, Sansome, satisfying, Seattle, segregation, Servier, ship, shock, strain, sublicense, substituted, surfaced, switch, switching, SynCore, synergistic, Talzenna, Tecentriq, transferase, ultimate, undermine, undermined, undetected, unforeseen, unsecured, validation, vedotin, vii, viii, Wuhan

PHAXIAM Therapeutics (PHXM) 20-F2022 FY Annual report (foreign)

Content analysis